AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
TL;DR
A graphical overview of the screening of 746,000 compounds for the inhibitory effects of α-synuclein aggregation gives rise to identification of novel inhibitors of α-synuclein aggregation that may help develop a cure for Parkinson's disease.
Blood plasma biomarkers identifying Alzheimer's disease (AD) neuropathology offer accessible and scalable alternatives to lumbar puncture and positron emission tomography (PET) scans, with potential efficiency gains in clinical trial recruitment.
Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder primarily treated by augmenting cholinergic neurotransmission. Traditional acetylcholinesterase inhibitors (AChEIs) offer modest symptomatic relief but often lack disease-modifying capabilities.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.